CL2021001260A1 - Anticuerpos anti-sirpa humanizados - Google Patents
Anticuerpos anti-sirpa humanizadosInfo
- Publication number
- CL2021001260A1 CL2021001260A1 CL2021001260A CL2021001260A CL2021001260A1 CL 2021001260 A1 CL2021001260 A1 CL 2021001260A1 CL 2021001260 A CL2021001260 A CL 2021001260A CL 2021001260 A CL2021001260 A CL 2021001260A CL 2021001260 A1 CL2021001260 A1 CL 2021001260A1
- Authority
- CL
- Chile
- Prior art keywords
- humanized anti
- sirpa antibodies
- treatment
- humanized
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18206594 | 2018-11-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021001260A1 true CL2021001260A1 (es) | 2021-12-24 |
Family
ID=64331834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021001260A CL2021001260A1 (es) | 2018-11-15 | 2021-05-13 | Anticuerpos anti-sirpa humanizados |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12180295B2 (https=) |
| EP (1) | EP3880707A1 (https=) |
| JP (1) | JP7451520B2 (https=) |
| CN (1) | CN113412279B (https=) |
| AU (1) | AU2019378101B2 (https=) |
| BR (1) | BR112021009275A2 (https=) |
| CA (1) | CA3118966A1 (https=) |
| CL (1) | CL2021001260A1 (https=) |
| IL (1) | IL282756A (https=) |
| MX (1) | MX2021005761A (https=) |
| MY (1) | MY204673A (https=) |
| SG (1) | SG11202104431PA (https=) |
| WO (1) | WO2020099653A1 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11779642B2 (en) | 2016-12-09 | 2023-10-10 | Alector Llc | Anti-SIRP-alpha antibodies and methods of use thereof |
| US11976119B2 (en) | 2018-05-25 | 2024-05-07 | Alector Llc | Anti-SIRPa antibodies and methods of use thereof |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS66062B1 (sr) | 2016-04-14 | 2024-11-29 | Ose Immunotherapeutics | Nova anti-sirpa antitela i njihove terapijske primene |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| CN118267470A (zh) * | 2017-04-13 | 2024-07-02 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
| MX2020009774A (es) | 2018-03-21 | 2020-10-08 | Alx Oncology Inc | Anticuerpos contra proteína alfa reguladora de señal y métodos de uso. |
| AU2021378152A1 (en) * | 2020-11-11 | 2023-06-22 | Daiichi Sankyo Company, Limited | COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPα ANTIBODY |
| CN112574310B (zh) * | 2020-12-11 | 2023-05-05 | 浙江博锐生物制药有限公司 | 抗SIRPα抗体及其用途 |
| CN114790241B (zh) * | 2021-01-26 | 2024-12-13 | 北京免疫方舟医药科技有限公司 | 抗tigit抗体及其应用 |
| BR112023025194A2 (pt) * | 2021-06-04 | 2024-02-27 | Boehringer Ingelheim Int | Anticorpos anti-sirp-alfa |
| EP4619435A1 (en) | 2022-11-16 | 2025-09-24 | Boehringer Ingelheim International GmbH | Predictive efficacy biomarkers for anti-sirpa antibodies |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| AU1701001A (en) | 1999-11-30 | 2001-06-12 | Eberhard-Karls-Universitat Tubingen Universitatsklinikum | Antibodies against signal regulator proteins |
| CN103172731A (zh) | 2004-07-15 | 2013-06-26 | 赞科股份有限公司 | 优化的Fc变体 |
| DK2474557T3 (da) | 2007-07-16 | 2014-11-10 | Genentech Inc | Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| CA2752373C (en) | 2009-02-20 | 2017-10-10 | To-Bbb Holding B.V. | Glutathione-based drug delivery system |
| CN101880324B (zh) * | 2010-05-25 | 2012-10-17 | 中国人民解放军第二军医大学 | 一种抗人SIRPα的单克隆抗体及其细胞株、制备方法和应用 |
| RU2597831C2 (ru) | 2011-01-19 | 2016-09-20 | Кантаргия Аб | Анти-il1rap антитела и их применение при лечении людей |
| MX2013014789A (es) * | 2011-06-16 | 2014-01-20 | Novartis Ag | Proteinas solubles para utilizarse como productos terapeuticos. |
| WO2013056352A1 (en) | 2011-10-19 | 2013-04-25 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
| WO2013150043A1 (en) | 2012-04-05 | 2013-10-10 | F. Hoffmann-La Roche Ag | Bispecific antibodies against human tweak and human il17 and uses thereof |
| EP3795215A1 (en) | 2012-05-30 | 2021-03-24 | Chugai Seiyaku Kabushiki Kaisha | Target tissue-specific antigen-binding molecule |
| MX2015008534A (es) | 2012-12-26 | 2017-07-04 | Oncosynergy Inc | COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS. |
| WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| CN103665165B (zh) * | 2013-08-28 | 2016-02-24 | 江苏匡亚生物医药科技有限公司 | 一种靶向人CD47-SIRPα信号通路的双特异性抗体及其制备方法和用途 |
| AU2015229448B2 (en) * | 2014-03-11 | 2020-09-03 | The Board Of Trustees Of The Leland Stanford Junior University | Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies |
| HUE046661T2 (hu) * | 2014-08-15 | 2020-03-30 | Merck Patent Gmbh | SIRP-alfa immunglobulin fúziós proteinek |
| CA2994935A1 (en) | 2015-05-18 | 2016-11-24 | Ab Initio Biotherapeutics, Inc. | Sirp polypeptide compositions and methods of use |
| JP7078533B2 (ja) | 2015-10-21 | 2022-05-31 | オーエスイー イムノセラピューティクス | 炎症促進性細胞へのマクロファージ分極を改変して癌を治療するための抗ＳＩＲＰａ化合物 |
| SG11201808465UA (en) * | 2016-04-14 | 2018-10-30 | Ose Immunotherapeutics | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS |
| KR102878970B1 (ko) | 2016-08-03 | 2025-10-30 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항-SIRPalpha 항체 요법의 대식세포 증진 효능에서 Fc 수용체 참여의 붕괴 |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| CN118027200A (zh) * | 2016-12-09 | 2024-05-14 | 艾利妥 | 抗SIRPα抗体及其使用方法 |
| CN118267470A (zh) * | 2017-04-13 | 2024-07-02 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
| CN118271443A (zh) | 2017-05-16 | 2024-07-02 | 拜奥迪斯私人有限公司 | 抗SIRPα抗体 |
| WO2019023347A1 (en) | 2017-07-26 | 2019-01-31 | Forty Seven, Inc. | ANTI-SIRP-ALPHA ANTIBODIES AND ASSOCIATED METHODS |
-
2019
- 2019-11-15 CA CA3118966A patent/CA3118966A1/en active Pending
- 2019-11-15 EP EP19808550.8A patent/EP3880707A1/en active Pending
- 2019-11-15 CN CN201980088956.2A patent/CN113412279B/zh active Active
- 2019-11-15 MX MX2021005761A patent/MX2021005761A/es unknown
- 2019-11-15 JP JP2021526658A patent/JP7451520B2/ja active Active
- 2019-11-15 AU AU2019378101A patent/AU2019378101B2/en active Active
- 2019-11-15 WO PCT/EP2019/081523 patent/WO2020099653A1/en not_active Ceased
- 2019-11-15 MY MYPI2021002647A patent/MY204673A/en unknown
- 2019-11-15 US US17/292,182 patent/US12180295B2/en active Active
- 2019-11-15 SG SG11202104431PA patent/SG11202104431PA/en unknown
- 2019-11-15 BR BR112021009275A patent/BR112021009275A2/pt unknown
-
2021
- 2021-04-28 IL IL282756A patent/IL282756A/en unknown
- 2021-05-13 CL CL2021001260A patent/CL2021001260A1/es unknown
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11779642B2 (en) | 2016-12-09 | 2023-10-10 | Alector Llc | Anti-SIRP-alpha antibodies and methods of use thereof |
| US12226482B2 (en) | 2016-12-09 | 2025-02-18 | Alector Llc | Anti-SIRP-alpha antibodies and methods of use thereof |
| US11976119B2 (en) | 2018-05-25 | 2024-05-07 | Alector Llc | Anti-SIRPa antibodies and methods of use thereof |
| US12258410B2 (en) | 2018-05-25 | 2025-03-25 | Alector Llc | Anti-SIRPα antibodies and methods of use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019378101B2 (en) | 2025-10-16 |
| WO2020099653A1 (en) | 2020-05-22 |
| IL282756A (en) | 2021-06-30 |
| BR112021009275A2 (pt) | 2022-01-04 |
| JP7451520B2 (ja) | 2024-03-18 |
| US20210388107A1 (en) | 2021-12-16 |
| US12180295B2 (en) | 2024-12-31 |
| MY204673A (en) | 2024-09-09 |
| JP2022509065A (ja) | 2022-01-20 |
| AU2019378101A1 (en) | 2021-05-27 |
| CA3118966A1 (en) | 2020-05-22 |
| SG11202104431PA (en) | 2021-05-28 |
| CN113412279A (zh) | 2021-09-17 |
| KR20210093270A (ko) | 2021-07-27 |
| CN113412279B (zh) | 2024-09-24 |
| MX2021005761A (es) | 2021-08-11 |
| EP3880707A1 (en) | 2021-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003266A1 (es) | Anticuerpos anti-sirpalfa. | |
| CL2021001260A1 (es) | Anticuerpos anti-sirpa humanizados | |
| CO2021001912A2 (es) | Composiciones anti-cd112r y métodos | |
| MX2016006726A (es) | Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer. | |
| PH12020500671A1 (en) | Antibodies specific for gucy2c and uses thereof | |
| CL2018003758A1 (es) | Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458) | |
| CO2019007298A2 (es) | Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos | |
| MX2020012286A (es) | Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t. | |
| MX2023014569A (es) | Anticuerpos anti-sirpa. | |
| CL2018002012A1 (es) | Derivados de maitansinoide, conjugados de los mismos y métodos de uso. | |
| MX2020012091A (es) | Composiciones anti-cd24 y usos de las mismas. | |
| BR112015032690A2 (pt) | uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir crescimento tumoral e metástases | |
| EA201691824A1 (ru) | АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ | |
| BR112015027309A2 (pt) | anticorpo, composição, método de tratamento e uso de um anticorpo | |
| EA202191257A1 (ru) | Противораковая терапия на основе иммуноцитов, связывающих liv1 | |
| MX2019010040A (es) | Composiciones y métodos para el tratamiento del cáncer. | |
| MX2017001599A (es) | Anticuerpos novedosos y sus usos. | |
| MX374290B (es) | Combinación de un anticuerpo anti cd20 con un inhibidor de btk para usarse en el tratamiento de cáncer. | |
| PE20160753A1 (es) | Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40 | |
| BR112015029386A2 (pt) | uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer | |
| EA201692100A1 (ru) | Новые антитела против rnf43 и способы их применения | |
| BR112017023517A2 (pt) | anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20 | |
| BR112016017112A2 (pt) | Composições de apilimod e métodos de uso das mesmas | |
| BR112015027474A8 (pt) | anticorpo, composição, método de tratamento do paciente que sofre de câncer e uso de um anticorpo. | |
| MX2018007818A (es) | Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso. |